JNJ-40255293, a Novel Adenosine A2A/A1 Antagonist with Efficacy in Preclinical Models of Parkinson’s Disease-Reference-Cited by-同舟云学术

JNJ-40255293, a Novel Adenosine A2A/A1 Antagonist with Efficacy in Preclinical Models of Parkinson’s Disease

Published:2014-09-24 Issue:10 Volume:5 Page:1005-1019
ISSN:1948-7193
Container-title:ACS Chemical Neuroscience
language:en
Short-container-title:ACS Chem. Neurosci.

Author:

Atack John R.¹,Shook Brian C.²,Rassnick Stefanie²,Jackson Paul F.²,Rhodes Kenneth²,Drinkenburg Wilhelmus H.¹,Ahnaou Abdallah¹,te Riele Paula¹,Langlois Xavier¹,Hrupka Brian¹,De Haes Patrick¹,Hendrickx Herman¹,Aerts Nancy¹,Hens Koen¹,Wellens Annemie¹,Vermeire Jef¹,Megens Anton A. H. P.¹

Affiliation:

1. Janssen Research and Development, Turnhoutseweg 30, Beerse B-2340, Belgium

2. Janssen Research and Development, Welsh and McKean Roads, Spring House, Pennsylvania 19477, United States

Publisher

American Chemical Society (ACS)

Subject

Cell Biology,Cognitive Neuroscience,Physiology,Biochemistry,General Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/cn5001606

Reference63 articles.

1. Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment

2. Priorities in Parkinson's disease research

3. Levodopa in the treatment of Parkinson's disease: Current controversies

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Experimental models of Parkinson's disease: Challenges and Opportunities;European Journal of Pharmacology;2024-10

2. Adenosine A2A receptors and sleep;International Review of Neurobiology;2023

3. A2A adenosine receptor agonists, antagonists, inverse agonists and partial agonists;International Review of Neurobiology;2023

4. The regulation of circadian entrainment in mice by the adenosine the A2A/A1 receptor antagonist CT1500;Frontiers in Physiology;2022-12-20

5. Indane-1,3-Dione: From Synthetic Strategies to Applications;Molecules;2022-09-14